Pharmaceutical Development
Download
1 / 43

Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Wa - PowerPoint PPT Presentation


  • 171 Views
  • Uploaded on

Pharmaceutical Development. Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Waterfront Cape Town, South Africa Date: 16 to 20 April 2007. Pharmaceutical Development. Analytical Method Development

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Protea Hotel Victoria Junction, Wa' - cleary


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Slide1 l.jpg

Pharmaceutical Development

Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations

Protea Hotel

Victoria Junction, Waterfront

Cape Town, South Africa

Date: 16 to 20 April 2007


Pharmaceutical development l.jpg
Pharmaceutical Development

Analytical Method Development

Presenter: János Pogány, pharmacist, PhD

[email protected]

WHO expert


Analytical method development l.jpg
Analytical Method Development

Outline and Objectives of presentation

  • Introduction, guidelines

  • Dossier requirements

    • Assay

    • Related substances

    • Other issues

  • Main points again


Training workshop on pharmaceutical development with focus on paediatric formulations l.jpg

Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations

Introduction, guidelines


Interchangeability ic l.jpg
Interchangeability (IC) on Paediatric

INTERCHANGEABILITY (IC) OF MULTISOURCE FPPs = (ESSENTIAL SIMILARITY WITH INNOVATOR FPP) =

PHARMACEUTICAL EQUIVALENCE (PE) + BIOEQUIVALENCE (BE)

IC=PE+ BE


Pharmaceutical equivalence l.jpg
Pharmaceutical equivalence on Paediatric

  • FPPs meet same or comparable standards (e.g., marketing authorization, analytical methods)

    • Same API(chemical and physical equivalence)

    • Same dosage form and route of administration

    • Samestrength

    • Comparable labeling

  • Pharmaceutical development equivalence

  • Stability equivalence

  • WHO-GMP(manufacturing equivalence)


Prequalification requirements l.jpg
Prequalification requirements on Paediatric

  • Analytical method validation is required by WHO for the prequalification of product dossiers. Non-compendial ARV APIs and FPPs were/are tested with methods developed by the manufacturer.

  • Analytical methods should be used within GMP and GLP environments, and must be developed using the protocols and acceptance criteria set out in the ICH guidelines Q2(R1)


Guidelines used in pqp l.jpg
Guidelines used in PQP on Paediatric

  • „WHO-GMP 4.11 „It is of critical importance that particular attention is paid to the validation of analytical test methods, automated systems and cleaning procedures.”

  • Appendix 4. Analytical method validation(in WHO Expert Committee on Specifications for Pharmaceutical Preparations. 40th Report. Geneva, WHO, 2006 (WHO Technical Report Series, No. 937). http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf

  • Validation of analytical procedures:text and methodology Q2(R1)ICH Harmonized Tripartite Guidelines, (2005) http://www.ich.org/LOB/media/MEDIA417.pdf


General requirements l.jpg
General requirements on Paediatric

  • Qualifiedandcalibrated instruments

  • Documented methods

  • Reliable reference standards

  • Qualified analysts

  • Sample selection and integrity

  • Change control


Measure of variation spread of data l.jpg
Measure of variation (spread of data) on Paediatric

68.26%

95.46%


Mean average chart l.jpg
Mean (average) chart on Paediatric

Abnormal variation of process – special causes

USL Upperspecification limit

Normal variation due to common causes

average = mean

LSL Lower specification limit

Abnormal variation of process – special causes


Capable process l.jpg

A on Paediatric lmost all the measurements of a stable process fall inside the specification limits

USL – LSL681012

Cp1.00 1.331.662.00

OoS results: .27%.6 ppm

64 ppm2 ppb

Capable process

http://www.itl.nist.gov/div898/handbook/pmc/section1/pmc16.htm


Nevirapine reference standard l.jpg
NEVIRAPINE – Reference Standard on Paediatric

System suitability requirement:

RSD is NMT 0.85%


Training workshop on pharmaceutical development with focus on paediatric formulations14 l.jpg

Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations

Dossier requirements


Use of analytical methods generics l.jpg
Use of analytical methods - on Paediatric Formulationsgenerics


A nalytical procedure characteristics l.jpg
A on Paediatric Formulationsnalytical procedure characteristics


Accuracy iso 5725 1 6 l.jpg
Accuracy - ISO 5725 1-6 on Paediatric Formulations

Source: ISO. 1994. ISO 5725 1-6: Accuracy (Trueness and Precision) of Measurement Methods and Results. ISO, Geneva, Switzerland.


Accuracy and precision l.jpg
Accuracy and precision on Paediatric Formulations

Inaccurate and imprecise

Precise

Accurate

Accurate and precise


Percent accuracy hypothetical figures l.jpg
Percent accuracy on Paediatric Formulations(hypothetical figures)

The data show that the recovery of analyte in spiked samplesmet theevaluation criterion for accuracy(100 ± 2.0% across 50–130% of target concentrations).


Percent accuracy hypothetical figures20 l.jpg
Percent accuracy on Paediatric Formulations(hypothetical figures)

Red line: LA Green lines: USL and LSL


Precision of any process l.jpg

The on Paediatric Formulationsprecision(VARIABILITY) of an analytical procedure is usually expressed as the standard deviation (S), variance (S2), or coefficient of variation (= relative standard deviation, RSD%.) of a series of measurements.

The confidence interval (CI) should be reported for each type of precision investigated.

Precision (of any process)

Measured meanReal mean

PRECISION


Repeatability of any process l.jpg

Repeatability on Paediatric Formulationsexpresses the precision(spread of the data, variability) under the same operating conditions over a short interval of time. Repeatability is also termed intra-assay precision.

Repeatability (of any process)

Measured mean

REPEATABILITY


Repeatability hypothetical figures l.jpg
Repeatability on Paediatric Formulations(hypothetical figures)

The repeatability precision obtained by one analyst in one laboratory was 1.25% RSD for the analyte and, therefore, meets the evaluation criterionof RSD ≤2%.


Intermediate precision and reproducibility of any process l.jpg

Intermediate precision on Paediatric Formulations expresses within-laboratories variations. #1, #2 and #3: different days, different analysts, different (manufacturing)equipment, etc.

Reproducibility expresses the precision between laboratories #1, #2 and #3 (collaborative studies, usually applied to standardization of methodology).(Transfer of technology)

Intermediate Precision and Reproducibility (of any process)

Measured means

Intermediate precision or Reproducibility


Intermediate precision ruggedness l.jpg
Intermediate precision on Paediatric Formulations(ruggedness)


Specificity selectivity l.jpg
Specificity (selectivity) on Paediatric Formulations

  • Specificity is the ability to assess unequivocally the analyte in the presence of components, which may be expected to be present. Typically these might include impurities, degradants and excipients.

  • An example of specificity criterion for an assay method is that the analyte peak will have baseline chromatographic resolution of at least 2.0 minutes from all other sample components

  • Stability indicating analytical methods should always be specific.


Identification a special case l.jpg
Identification – a special case on Paediatric Formulations

  • Diethylene glycol (DEG) in paediatric dosage forms has been implicated as the causative agent in numerous deaths since 1937. The victims were mainly children.

  • Illustrative analytical issues of investigation

    • IR identity test was able to detect DEG at about 20 %w/w

    • Testing of DEG in Glycerol (and in Propylene Glycol) was recommended with a LOD (sensitivity) of NLT 0.1 %. For detecting DEG at low levels, GC seemed preferable.

    • The assay was the most relevant test (accurate within ± 0.2%)

  • Illustrative regulatory issues

    • Legislation

    • GMP

  • Specificity is an essential but not sufficient characteristic of identification


Specificity hypothetical figures and data l.jpg
Specificity on Paediatric Formulations(hypothetical figures and data)

HPLC chromatograms of (a) API reference standard, (b) FPP and (c) placebo


Specificity degradants l.jpg
SPECIFICITY – degradants on Paediatric Formulations

There were no peaks in the placebo chromatogram at the retention times of nevirapine (N), methylparaben (MP) and propylparaben (PP) peaks.

*Sum of N, MP and PP peak areas. The three ingredients can be assessed in the presence of (non-expected) degradants. The peaks are homogeneous and pure. The method is selective, specific and stability-indicating.


Lod loq and snr l.jpg
LOD, LOQ and SNR on Paediatric Formulations

  • Limit of Quantitation (LOQ)

  • Limit of Detection (LOD)

  • Signal to Noise Ratio (SNR)

Peak BLOQ

Peak ALOD

noise

Baseline


Lod and loq hypothetical figures l.jpg
LOD and LOQ on Paediatric Formulations(hypothetical figures)


Lod and loq l.jpg
LOD and LOQ on Paediatric Formulations

  • The limit of detection (LOD) is defined as the lowest concentration of an analyte in a sample that can be detected, not quantified. It is expressed as a concentration at a specified signal:noise ratio (SNR), usuallybetween 3 and 2 :1.

  • In this study, the LOD was determined to be 0.086 μg/ml(Impurity 1) with a signal:noise ratio of 3.6 : 1

  • The limit of quantitation (LOQ) is defined as the lowest concentration of an analyte in a sample that can be determined with acceptable precision and accuracy under the stated operational conditions of the method. The ICH has recommended a signal:noise ratio (SNR) of 10:1.

  • The LOQ was 0.171 μg/ml(Impurity 1) with a signal:noise ratio of 11.3. The RSD for six injections of the LOQ solution was ≤2%.


Linearity l.jpg

Linearity on Paediatric Formulations expresses differences in precision at different points of a given range.

„The linearity of an analytical procedure is its ability (within a given range) to obtain test results, which are directly proportional to the concentration (amount) of analyte in the sample.”

Linearity

MeasuredReal

meanmeanPrecision


Linearity and range l.jpg
Linearity and range on Paediatric Formulations

Acceptance criterion: correlation coefficient should not be less than 0.9990


Linearity and range35 l.jpg
Linearity and range on Paediatric Formulations

  • Concentration range1.0–1.3 mg/ml (10–130% of the theoretical concentration in the test preparation, n=3)

  • Regression equation was found by plotting the means ofpeak area (y) against the analyte concentration (x) expressed in %:

    y = 36.124x -7.2984 (R2 = 0.9998).

  • The regression coefficient demonstrates an excellent relationship between peak area and concentration of analyte.

  • The analyte response is linear across 10-130% of the target nevirapine concentration.


Range minimum requirements l.jpg
Range (minimum requirements) on Paediatric Formulations

  • Assay of an API or a FPP: ±20% of the test concentration.

  • Content uniformity: ± 30% of the test concentration (unless a wider more appropriate range, based on the nature of the dosage form (e.g., metered dose inhalers), is justified).

  • Dissolution testing: ±20 % over the specified range.

  • Impurity: from the reporting level of an impurityto 120% of the specification. (Unusually potent or toxic impurities, LOD and LOQ should be commensurate with ICH requirement.)

  • If assay and purity are performed together as one test and only a 100% standard is used, linearity should cover the range from the reporting level of the impurities to 120% of the assay specification


Stability of analytical solution l.jpg

Stability on Paediatric Formulations (of the analytical solution) expressesvariationof the measured mean as a function of time.

#1 … First measurements

#2, #3, #4, …n Series of measurements of the same sample within a relatively short period of time.

Stability of analytical solution

Stability Measured means


Stability of test analytical solution l.jpg
Stability of test analytical solution on Paediatric Formulations

An analytical solution prepared from Nevirapine 50mg/5ml Oral Suspension was spiked with Impurity-1 at specification level and stored in a capped volumetric flask on a laboratory bench at uncontrolled room temperature under normal lighting conditions for 25 hours.

Conclusion: the stability of the analytical solution of Impurity-1 is not a source of variation.


Sensitivity and robustness l.jpg
Sensitivity and robustness on Paediatric Formulations


Robustness l.jpg
Robustness on Paediatric Formulations


Methods for cleaning validation l.jpg
Methods for cleaning validation on Paediatric Formulations

  • Method for assay and related substances used in stability studies of API and FPP

    • Specificity (in samples taken from a cleaning assessment)

    • Linearity of response (from 50% of the cleaning limit to 10x this concentration; R2≥0.9900; )

    • Precision

      • Repeatability (RSD ≤5%),

      • intermediate precision [ruggedness (USP)], and

      • reproducibility

    • Limits of detection and quantitation

    • Accuracy or recovery from rinsate (≥80%), swabs (≥90%), and process surface (≥ 70%)

    • Range (lowest level is at least 2x higher than LOQ)


Main points again l.jpg
Main Points Again on Paediatric Formulations

  • Analytical procedures play a critical role in pharmaceutical equivalence and risk assessment/ management:

    • establishment of product-specific acceptance criteria, and

    • stability of APIs and FPPs.

  • Validation should demonstrate that the analytical procedure is suitable for its intented purpose.

  • HPLC systems and method validation deserves special attentionduring the assessment of dossiers for prequalification.


Slide43 l.jpg

THANK YOU on Paediatric Formulations


ad